`
`
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`Plaintiffs,
`
`Defendants.
`
`
`
`
`
`
`C.A. No. 16-1221 (LPS)
`CONSOLIDATED
`
`BAYER HEALTHCARE LLC and BAYER
`HEALTHCARE PHARMACEUTICALS
`INC.,
`
`
`
`
`
`TEVA PHARMACEUTICALS USA, INC.,
`et al.,
`
`
`
`
`
`
`
`
`
`
`
`v.
`
`
`
`
`
`JOINT CLAIM CONSTRUCTION CHART
`
`In accordance with Paragraph 11 of the Scheduling Order, Plaintiffs Bayer HealthCare
`
`LLC and Bayer HealthCare Pharmaceuticals Inc. (collectively, “Bayer” ), and Defendants Teva
`
`Pharmaceuticals USA, Inc. (“Teva”), Apotex Inc. and Apotex Corp. (“Apotex”) respectfully
`
`submit this Joint Claim Construction Chart.
`
`Attached as Exhibit A is a table identifying the parties’ proposed claim construction
`
`positions with respect to certain terms in the asserted claims of U.S. Patent Nos. 8,680,124 and
`
`9,458,107. No claim term contained in any of the asserted claims of U.S. Patent No. 7,351,834
`
`or 8,637,553 is proposed for construction.
`
`
`
`
`
`Case 1:16-cv-01221-LPS Document 52 Filed 05/23/18 Page 2 of 5 PageID #: 383
`
`
`
`
`
`
`
`
`
`SHAW KELLER LLP
`
`/s/ Karen E. Keller
`
`
`
`
`John W. Shaw (#3362)
`Karen E. Keller (#4489)
`David M. Fry (#5486)
`1105 North Market Street
`12th Floor
`Wilmington, DE 19801
`(302) 298-0701
`jshaw@shawkeller.com
`kkeller@shawkeller.com
`dfry@shawkeller.com
`
`Attorneys for Defendant Teva Pharmaceuticals
`USA, Inc.
`
`MORRIS JAMES LLP
`
`/s/ Kenneth L. Dorsney
`
`
`
`
`Kenneth L. Dorsney (#3726)
`500 Delaware Avenue, Suite 1500
`Wilmington, DE 19801-1494
`(302) 888-6855
`kdorsney@morrisjames.com
`
`Attorneys for Defendants Apotex Inc. and
`Apotex Corp.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`MORRIS, NICHOLS, ARSHT & TUNNELL LLP
`
`/s/ Derek J. Fahnestock
`
`
`
`
`Jack B. Blumenfeld (#1014)
`Derek J. Fahnestock (#4705)
`Anthony D. Raucci (#5948)
`1201 North Market Street
`P.O. Box 1347
`Wilmington, DE 19899
`(302) 658-9200
`jblumenfeld@mnat.com
`dfahnestock@mnat.com
`araucci@mnat.com
`
`Attorneys for Plaintiffs Bayer HealthCare LLC
`and Bayer HealthCare Pharmaceuticals Inc.
`
`
`
`May 23, 2018
`
`
`2
`
`
`
`Case 1:16-cv-01221-LPS Document 52 Filed 05/23/18 Page 3 of 5 PageID #: 384
`
`
`
`
`
`Claim Term/Phrase
`
`All asserted claims
`Preambles
`
`
`Claims 1, 2, 4, 29
`“acquired resistance”
`
`
`
`Claim Term/Phrase
`
`
`Claims 1, 29-31
`“an effective amount”
`
`Exhibit A
`
`Proposed Constructions for U.S. Patent No. 8,680,124 (’124 patent)1:
`
`Proposed Construction Agreed to By Bayer and Teva
`
`The preambles are limiting.
`
`
`resistant and/or substantially less responsive to the effects of the drug compared to initial
`responsiveness
`
`
`Bayer’s Proposed Construction and
`Supporting Intrinsic Evidence
`
`an amount which is effective to treat any
`symptom or aspect of the cancer or the tumor
`
`Intrinsic Evidence
`
`’124 Patent:
` col. 6, ll. 4-24
` claims 1, 29-31
`
`
`’124 Patent File History:
` originally filed specification and claims
`
`Teva’s Proposed Construction and
`Supporting Intrinsic Evidence
`
`an amount that is effective to combat, alleviate,
`reduce, relieve, or improve one or more of the
`symptoms associated with a cancer, including
`but not limited to amounts that cause tumor
`regression, cell death, apoptosis, necrosis;
`inhibit cell proliferation; tumor growth, tumor
`metastasis, tumor migration, tumor invasion;
`reduce disease progression; stabilize the
`disease; reduce or inhibit angiogenesis;
`prolong patient survival; enhance quality of
`life; and/or reduce the frequency, severity,
`intensity, and/ or duration of any adverse
`
`
`1 This patent is not at issue in the cases against Apotex Inc. and Apotex Corp., C.A. No. 16-1222 and C.A. No. 17-334.
`
`
`
`
`
`Case 1:16-cv-01221-LPS Document 52 Filed 05/23/18 Page 4 of 5 PageID #: 385
`
`
`
`symptoms or activities.
`
`Intrinsic Evidence
`
`’124 Patent:
` col. 6, ll. 4-24
` claims 3 and 28
`
`
`
` a
`
`
`
` subject that is resistant and/or substantially
`less responsive to the effects of imatinib
`compared to that subject’s initial
`responsiveness to imatinib
`
`Intrinsic Evidence
`
`’124 Patent:
` Title
` Abstract
` col. 1, l. 64 – col. 2, l. 4
` col. 2, ll. 12-46
` col. 3, ll. 3-14
` col. 3, ll. 42-44
` col. 4, ll. 36-50
` col. 6, ll. 41-55
` col. 7, ll. 1-4
` col. 18, ll. 36-41
`
` a
`
` subject who has been treated with imatinib (no
`construction necessary)
`
`Intrinsic Evidence
`
`’124 Patent:
` col. 1, l. 67 – col. 2, l. 4
` col. 4, ll. 51-54
` col. 6, ll. 25-27
` claims 1, 2, 4, 26-27, 29-31
`
`
`’124 Patent File History:
` originally filed specification and claims
`
`
`
`
`Claims 30, 31
`“a subject who has been
`treated with imatinib”
`
`
`
`
`
`
`
`2
`
`
`
`Case 1:16-cv-01221-LPS Document 52 Filed 05/23/18 Page 5 of 5 PageID #: 386
`
`Proposed Constructions for U.S. Patent No. 9,458,107 (’107 patent):
`
`Proposed Construction Agreed to By All Parties
`
` pharmaceutical composition
`
` A
`
`
`in an amount from 0.0001% to a maximum of 0.05%
`
`3
`
`
`
`
`Claim Term/Phrase
`
`Claims 3, 4, 12, 13, 14, 18, 20
`“A composition”
`
`
`Claims 1-4
`“in an amount equal to or less
`than 0.05%”
`
`
`
`
`
`
`